Search Results for "Odac Marqibo 2012"

20:55 EST 22nd November 2017 | BioPortfolio

Matching Channels


Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...

ATX-MS-1467 for patients with multiple sclerosis (MS)

ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the ...


Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...


Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing p...


Sequencing platforms in diagnostic laboratories may aid both patient management by detecting resistance associated mutations, and public health measures, by determining phylogenetic relationships be...

Matching News

CAR-T Cell Therapy Given Green Light by ODAC for B-Cell Acute Lymphoblastic Leukemia

ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.

Latest News From "The Pink Sheet" DAILY - Aveo's Tivozanib Faces ODAC May 2

Aveo's Tivozanib Will Face Challenging Survival Data At ODAC Review FDA's Oncologic Drugs Advisory Committee will consider the tyrosine kinase inhibitor for advanced renal cell carcinoma at a May 2 me...

Pfizer announces outcome of FDA's ODAC meeting for SUTENT in patients at high risk of recurrent renal cell carcinoma after surgery

Pfizer announced that the US Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvan...

ODAC split on Sutent for adjuvant RCC

ODAC greenlights Novartis’ CAR-T cell therapy CTL019

ODAC Gives Thumbs Up to Avastin Biosimilar

(MedPage Today) -- Unanimous recommendation for FDA approval

Much awaited FDA advisory panel delivers positive vote on CAR-T therapy

The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0)…

Can a medicine for bone health improve breast cancer outcomes?

In addition to being used for osteoporosis, bisphosphonates are currently the standard of care for patients whose breast cancer has spread to the bones. These drugs help strengthen the bones and reduc...

Matching PubMed Articles

Notice of Retraction and Replacement. Wansink B, Just DR, Payne CR. Can Branding Improve School Lunches? Arch Pediatr Adolesc Med. 2012;166(10):967-968. doi:10.1001/archpediatrics.2012.999.

Notice of Retraction. Wansink B, Just DR, Payne CR. Can Branding Improve School Lunches? Arch Pediatr Adolesc Med. 2012;166(10):967-968. JAMA Pediatr. doi:10.1001/archpediatrics.2012.999.

Deaths from Opioid Overdosing: Implications of Coroners' Inquest Reports 2008-2012 and Annual Rise in Opioid Prescription Rates: A Population-Based Cohort Study.

In the late 1990s multiple physicians and advocacy organizations promoted increased use of opioids for the treatment of acute, chronic and cancer pain. There has been an exponential growth in opioid p...

Keratitis secondary to Fusarium spp. in Spain 2012-2014.

To describe the clinical-epidemiological characteristics of a case series of fungal keratitis associated with Fusarium spp.., in Spain during the years 2012 to 2014.

The use of prophylactic dressings in the prevention of pressure ulcers: a literature review.

Pressure ulcers pose a significant burden to both patients and health care resources. There are an increasing number of studies that have examined the use of prophylactic dressings, and their ability ...

Search Whole site using Google

Quick Search
Advertisement Advertisement